EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
CH7233163 Sensitive: D – Preclinical
|
CH7233163 Sensitive: D – Preclinical
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
osimertinib + BLU-945 Sensitive: D – Preclinical
|
osimertinib + BLU-945 Sensitive: D – Preclinical
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
panitumumab + WX-0593 Sensitive: D – Preclinical
|
panitumumab + WX-0593 Sensitive: D – Preclinical
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
TAS3351 Sensitive: D – Preclinical
|
TAS3351 Sensitive: D – Preclinical
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
|
NSCLC
|
H002 Sensitive: D – Preclinical
|
H002 Sensitive: D – Preclinical
|